Elequin Capital, LP: JD position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Elequin Capital, LP on JD, newest first. How the timeline and the estimate are built.
Elequin Capital, LP held 9 JD shares at 2026-06-30 per its 13F-HR filed 2026-08-13.
the latest 13F is the newest step
- period ended2026-06-3013F 9 sharesChange vs previous 13F -158 shares
<0.01% of the 13F portfolio, value $229.
13F-HR 0001420506-26-001586 filed by Elequin Capital, LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2026-03-3113F 167 sharesChange vs previous 13F -275 shares
<0.01% of the 13F portfolio, value $4,938.
13F-HR 0001420506-26-000905 filed by Elequin Capital, LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F 442 sharesChange vs previous 13F +442 shares
<0.01% of the 13F portfolio, value $12,685.
13F-HR 0001420506-26-000513 filed by Elequin Capital, LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 0 sharesChange vs previous 13F -873 shares
13F-HR 0001420506-25-001034 filed by Elequin Capital, LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2024-12-3113F 873 sharesChange vs previous 13F -1,412 shares
<0.01% of the 13F portfolio, value $30,267.
13F-HR 0001420506-25-000630 filed by Elequin Capital, LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-09-3013F 2,285 sharesChange vs previous 13F not available
0.01% of the 13F portfolio, value $91,400.
13F-HR 0001420506-24-002571 filed by Elequin Capital, LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).